ABSTRACT: Many mutations in breast cancer exome sequences alter susceptibility to infections. An exhaustive analysis of all the mutations in exomes from 103 breast cancer cases found that more than 1,000 genes have a published association with some kind of infection, including all known tumor viruses. Altered susceptibility to infection was identified as a common thread connecting breast cancer mutations in genes traditionally classified as coding for diverse functions, including cell immunity, cell architectural barriers, stromal interactions, cell adhesion, DNA damage responses, translation, cell cycle control, metabolism, homeostasis, transport, and neurosensing. Infections and mutations can both contribute to cancer because they deregulate the same pathways. In many cases, infections make a contribution to cancer that is either known or biologically plausible. Interventions may be possible to prevent occult infections from cooperating with mutations to cause further cancer, metastasis, or other complications. The emerging list of infection-gene mutation associations is readily scalable to routine testing of large human data sets.
Introduction
Lesions are thought to become malignant because mutations accumulate over long periods to disable or deregulate essential cellular controls. Some mutations may activate proto-oncogenes to become uncontrolled oncogenes, and other mutations may inactivate tumor suppressor genes. About 15%-20% of cancers are known to be caused by tumor viruses or other infections. 1 Infectious and noninfectious cancers are considered as separate diseases and are even studied in separate disciplines. Relationships between infections and cancers have produced some notable successes, such as the ability to prevent some cancers of the cervix and the liver. In other organs, associations between a single individual infection and cancer have been difficult to reproduce. For example, breast cancers have been associated with very different infections including retroviruses (mouse mammary tumor virus [MMTV] and human endogenous retrovirus [HERV] ), a large double-stranded DNA virus (EpsteinBarr virus [EBV] ), and a small double-stranded DNA virus (human papilloma virus [HPV] ). Results linking any one of these infections to breast cancer are contradictory and difficult to reproduce. 2 Asymptomatic infections have spread tumor viruses through the population so that virtually everyone has been inoculated with tumor viruses such as EBV and HPV. Tumor viruses have been widely reported in normal breasts, so if viruses cause cancer, most women should probably develop breast cancer.
One reason this does not occur is because breast cancers may require mutations in genes that lead to compromised immunity. 3, 4 Gene mutations that deregulate the immune system, cellular architecture, or underlying metabolic support create errors in the signals that prevent viral infection and in signals that maintain resident tumor viruses in a latent state. In addition, some bacterial infections may cause chronic inflammation with continual cell proliferation in the presence of mutagens or the infecting bacteria may even release carcinogenic metabolites. [5] [6] [7] Under these scenarios, no matter what the infectious agent, mutations that damage host cell-protective mechanisms or normal cell functions would increase risks for cancers.
In breast cancer, gene mutations can alter the ability of the immune system to control cancer-causing infections in multiple ways and high percentages of mutations can be linked to damage to protective signals. 3, 4 Some host mutations interfere with signals that cells are under attack and that protective boundaries have become abnormal. Signals connecting innate and adaptive immunity may not work properly. Communication between cells and the extracellular matrix may be damaged by mutation. Changes in cellular morphology and metabolism are needed to convert normal cells into cancer or viral factories. Mutations in genes encoding proteins essential for transcription, mRNA splicing, or translation can facilitate or inhibit viral takeover.
Materials and Methods
Data used. Breast cancers blindly used for analysis were from publicly available data for sporadic breast cancers. 50 As previously described, 3, 4, 49 studies selected were heavily weighted for ductal cancers because ductal cancer is the most common form. The whole-exome sequences came from 103 matched sporadic female breast cancer/normal pairs from Mexico (54 tumors; median age, 54) and Vietnam (49 tumors; median age, 48) . 50 Eighty-seven of these 103 sporadic breast cancers were invasive ductal. Sixteen cancers from the group were tubular, medullary, mucinous, mixed, lobular, and ductal carcinoma in situ (DCIS). Over 60% of the breast cancers were stage II, but about 20% were stage III. Eight (15%) of the cancers from Mexico and three (6%) from Vietnam were stage I. Nine (17%) of the breast cancers were stage 0 (DCIS). These breast cancer exomes had 4,985 candidate somatic gene mutations that involved 3,807 different genes. 50 Twelve women from Vietnam were postmenopausal and the remaining 27 were premenopausal. The menopause status of the women from Mexico is not known but 21 were younger than 50 years. The ages of the women ranged from 31 to 92. 50 Lists of oncogenes and tumor suppressors were taken from lists compiled for the CancerGenes website.
Databases used and methods of functional analysis have been previously described. 3, 4 Briefly, the functions of each testable gene with an exome mutation were determined by searching through all the information published about the gene on PubMed, Google scholar, and/or The Online Mendelian Inheritance of Man. Many original papers were also consulted. Functional analyses were limited to the most recent 100 references published. After the normal function of a gene was determined, further searches tested the name of the gene against "infection, virus, bacteria," etc. In many cases the relationships among genes and infections could only be found by studying publications describing the life cycle of candidate microorganisms. Based on similarities to retroviruses, retrotransposons were tentatively classified as infectious in origin. About six retrotransposons were associated with mutations and had no significant effect on the results. An initial classification of genes related to innate immunity was obtained by comparing genes listed in innate immune databases. [57] [58] [59] Statistical analyses were done with Excel and StatsDirect.
Results
Mutations focus on immune signaling. Many different signaling pathways are affected by mutations in different breast cancers but a common thread is that they alter responses to infection. In many cases, the altered responses are to infections known to cause cancer. This is based on studying 4,985 mutations involving a total of 3,807 genes in 103 sporadic breast cancer exomes. Figure 1 is a pie chart showing the numbers of mutated genes placed into broad functional categories. Of the 4,985 total exome mutations, most of them (3,427 mutations) had some relationship to signals essential for immunity or for structural and architectural barriers needed to prevent or sequester infections.
Of the 3,807 different genes with mutations, only 2,947 could be tested (Fig. 1 ). Among these 2,947 genes with mutations are 1,077 different genes (36.5%) that are known to respond to some infection. In all, 774 mutations occurred in genes encoding products for more diverse cellular functions: homeostasis, metabolism, hormonally mediated phenomena, cell cycle, replication, transcription, translation, etc. Among these 774 mutations, at least 287 were associated with some kind of infection. Table 1 shows how the mutations are distributed among the most prevalent infections. There are many opportunities for associations among mutations and known cancer-causing microbes. All known cancer-causing microbes are represented among these infections. Human immunodeficiency virus (HIV) appears most frequently, but this may merely reflect the intensity with which AIDS has been studied. Nonetheless, in the presence of a damaged immune system, associations between gene mutations and HIV infection probably raise the risk for AIDS-defining malignancies such as Kaposi sarcoma, non-Hodgkin lymphoma, and cervical cancer. Other cancer causing viruses including EBV, hepatitis B virus (HBV), hepatitis C virus (HCV), and HPV are all represented about equally in Table 1 . Helicobacter pylori occurs roughly half as often; human herpes virus type 8 (HHV-8), Dengue virus (DENV), and human T-cell leukemia virus (HTLV) slightly less than that. Associations with other viruses such as human cytomegalovirus (HCMV), influenza A virus (IAV), and with bacteria, mycobacteria, fungi, parasites, and prions. There were a few infections associated with mutations in transposon and retrotransposon genes (Tables 1 and 2 ). (Gene symbols and microorganism abbreviations are inserted before the author contribution section of this paper). To illustrate how this information might translate into actionable interventions, 41 demonstration breast cancers were selected at random from the list of 103 breast cancers. A random number generator was used to prevent bias or unwitting cherry-picking of the data. At the 90% confidence level, the 41 breast cancers are sufficient to show that multiple infections are universal and typical of every one of the 103 sporadic breast cancers. Many genes encode proteins with multiple functions, so seemingly disparate signals modified by infection often have some connection to immune signals, support of immune responses or cell architectural barriers, or to a variety of other functions. All these processes change susceptibility to groups of infections. All breast cancers in Table 2 have mutations associated with multiple infections, including viruses, bacteria, fungi, parasites, and prions.
In some breast cancers, mutations may favor a single infection. Patient BR-M-116 had 15 mutations and BR-M-045 had 8 mutations that altered the risk from EBV infection. BR-M-045 had seven mutations that altered HCV risk. BR-M-123 and BR-M-105 had 12 and 7 mutations, respectively, that altered the risk from carcinogenic HPV infection. BR-M-105, BR-M-116, and BR-V-002 had seven mutations that altered risk from HHV-8 infections ( Table 2 ). Mutations that alter risks for bacterial infections were also found in the breast cancers and must represent a substantial burden. Individual single mutations in Table 2 were often associated with multiple infections.
Associations between breast cancer mutations and infections are biologically plausible. To determine whether there were biologically plausible relationships between breast cancer mutations, infection, and known signaling pathways, mutations were tested against multiple known signaling pathways. As examples, immune [8] [9] [10] [11] [12] and protein translation signaling pathways [13] [14] [15] in response to infections are diagrammed in Figures 2 and 3 
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Journal of Genomes and exomes 2015:4 Figure 2 . examples of steps in innate immune pathways altered by mutation in breast cancers. Breast cancers having mutations in a given gene are listed in red boxes with mutations being assumed as inhibitory. a few infections from the broad range of infections that interact with the pathways shown are arbitrarily selected to illustrate the potential for relationships among infections and gene mutation to exacerbate cancer. orange boxes indicate inhibitory signals from infections, and light blue boxes indicate the gene is stimulated by the infection. In some cases, the protein product from the infection that affects the signal is given before the infection. Tables 2 and 3 give infections that are associated with damage to genes encoding many of the steps in the pathways shown.
Mutations in breast cancer exome sequences
9
Journal of Genomes and exomes 2015:4 There are many opportunities for breast cancer mutations and associated infections to exacerbate cancer risks. Only a few arbitrarily selected interactions are shown (Figs. 2 and 3) among components in these pathways versus infections, but they illustrate how known tumor viruses or other infections can evade immune responses and cooperate with, substitute for, or antagonize breast cancer mutations. Table 2 gives more detail of examples linking breast cancer mutations and specific infections or groups of infections. Table 3 uses more traditional classification systems to separate infection-associated breast cancer mutations into diverse processes that they affect: innate and adaptive immunity, cell adhesion and tissue architecture, DNA damage response, protein transcription, mRNA splicing, RNA processing, protein translation, cell cycle control, metabolism, nucleocytoplasmic transport, and protein trafficking. Table 3 is intended to illustrate that the 1,077 different genes linked to infection can encode for widely different functions. There are only about 200 different genes used as examples in Table 3 , but a current working list of all the mutations, the genes affected, and the associated infections is available as Supplementary Material. Beyond immunity and protein translation, most traditional cellular functions can be altered, deregulated, or subverted by infections. For example, normal cell morphology and metabolism in virally infected cells must be altered to convert the cells into viral factories. Changes in ionic strength or pH can sometimes affect infection such as by facilitating viral uncoating. These traditional functions are also targeted by mutation, although not necessarily at the same points ( Figs. 2 and 3 ). An additional signaling pathway for metabolic generation of energy (not shown) further supports the biological plausibility of mutation and infection associations.
Examples showing mutation in diverse functions alter risks for infection.
Breast cancer mutations damage genes encoding for proteins in immune signaling pathways. Brief explanations for some of the steps shown in Figure 2 are given below. Multiple infections, even those not linked to cancer, can affect the response to tumor viruses and to mutations. For example, four breast cancers have mutations in a proteasome component, and many breast cancers have mutations that affect Table 3 . Individual breast cancer mutations deregulate the same cell signals as infections over a wide variety of processes. Histone H1 regulates silencing of Ifn regulated transcription and its chaperone Taf-1. 129 other histones participate in dna structures that affect retroviral integration sites. Chromatin structure is important in determining mutation rate
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JeV, eBV 16 and by many breast cancer mutations as well ( Fig. 1 and Table 3 ).
MyD88 (myeloid differentiation primary response 88) is an adaptor for Toll-like receptors (TLRs) on the cell and endosomal membrane and is essential to produce inflammatory cytokines and Interferons (IFN; Fig. 2 ). The RTA pro tein (the transcription activator and lytic switch) from the HHV-8 virus degrades MyD88 and blocks TLR signaling (Fig. 2) . HBV and HCV also inhibit MyD88 and alter its downstream signaling. 17, 18 Other viruses also target
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MyD88. Breast cancer mutations in MyD88 itself were not found, but breast cancer mutations affected many of the steps downstream of the MyD88 gene product (Fig. 2 ). IRAK2 and IRAK3 (Interleukin 1 Receptor-Associated Kinases) are mutated in different breast cancers, damaging the control of inflammatory cytokine production (Fig. 2 ). IRAK3 interacts with IRAK2 and inhibits IRAK2-mediated phosphorylation of eIF4E, establishing a connection with protein translation. This prevents translation of inflammatory cytokines and downregulates TLR responses. 19 These genes are associated with multiple infections (Table 3) . 20 The endosomal TLR3 gene has missense mutations in two breast cancers (Table 3 ). In endosomes (green circle in Fig. 2 ), TLR3 binds tumor virus double-stranded RNA (dsRNA) such as those from lysed pathogens and activates signaling to the nucleus to produce antiviral cytokines such as IFNs (Fig. 2) . 21, 22 TLR3 is essential to respond to other viruses listed in Table 3 . RIG-1 (retinoic acid-inducible gene 1-like helicase) is a cytoplasmic recognition sensor for viral RNAs, and RIG-1-mediated pathways attract both mutation and infection ( Fig. 2 and Table 3 ). Multiple infections and breast cancer mutations focus on RIG-1-mediated signaling (Fig. 2) .
Twenty mutations in 17 different breast cancers involved dynein heavy chains (Table 3) , which transport cargo along microtubules and maintain cytoplasmic architecture. Innate cellular defenses against retroviral infection include restriction factors such as Tripartite Motif-Containing Protein 5 (TRIM5 protein). TRIM5a is present in the cytoplasm, where it interferes with retroviruses shortly after they enter the cell. The restriction factor then inhibits viral uncoating and reverse transcription. The dynein complex is essential to transport TRIM5a protein or complexes containing TRIM5a along microtubules to interrupt cytoplasmic retroviral infections. Crippling the activity of dynein motors or dynein complexes or interfering with microtubule structure decreases the ability of TRIM5a to protect against retroviral infection.
23
IFNs can transmit signals to the Janus Kinase -Signal Transducer and Activator of Transcription (JAK-STAT) pathway via receptors in uninfected cells 24 to protect them from infection. Abnormal regulation of the JAK-STAT pathway occurs in human cancers in diverse organs 25 and at least seven breast cancers have mutations affecting JAK-STAT signaling (Fig. 2) . The JAK-STAT pathway is inhibited by many viruses including Varicella zoster virus (VZV), 26 HBV, 27 and HCV.
28
Breast cancer mutations interfere with intrinsic immunity. Nonsense-mediated decay (NMD) factors sense premature termination codons associated with translation of some viral sequences. Figure 3 (bottom) shows inhibition or activation of NMD by several viruses. Six breast cancers have mutations in factors required for NMD (Fig. 3 and Table 3 ).
Infection and mutation can both affect the DNA damage response. Damage to genes encoding pathways to repair DNA damage occurs in at least 18 different breast cancers (Table 3 and Fig. 2 ). Viral infections can break chromosomes, activating innate immune responses to target infected or transformed cells. Viruses can pervert host DNA repair to promote inte gration of viral DNA into host DNA and can limit other infections. Chromosomes in virally infected cells can sometimes have a remarkable resemblance to hereditary cancer-prone diseases that have inactive genes required for DNA double strand break repairs. Mutations affecting genomic stability increase infection risks.
The protein signals required for DNA damage responses include ATM, ATR, BRCA1, BRCA2, PALB2, RAD50, RAD51, Fanconi proteins, XPC, and PRKC1. Mutations in many of these genes can be inherited and lead to hereditary cancer predispositions. Chromatid exchanges and aberrations typical of Fanconi anemia and BRCA2 infections can result from viral infections. Mutations in ATM (four breast cancers), BRCA1, BRCA2, and interacting partners (seven breast cancers) and Fanconi proteins (three breast cancers) render the genome less stable by influencing DNA repair. Homozygous ATM mutations are well known to increase infection risks. Table 3 shows infection risks increased by BRCA and Fanconi gene mutations. Breast cancer mutations affecting base excision and nucleotide excision repair pathways also increase risks for infections (Table 3 ). In turn, infection by H. pylori, for one, causes mutations by several mechanisms including downregulating major DNA repair pathways.
Infections associated with mutations affect innate immunity signals. Granzymes are serine proteases without antigen receptors that kill target cells and pathogens directly. Perforin (PRF1) is the chief effector for Natural Killer cell (NK)-mediated cytolysis. Table 3 shows that granzyme and perforin deficits are associated with many infections, both viral and nonviral. Granzyme A (GZMA) and Granzyme H (GZMH) genes are mutated in two breast cancers and PRF1 is mutated in another (Fig. 2, right side) .
Damage to genes essential for neutrophil functions. In addition to granzymes, at least 10 other genes (AKT1, AOC3, BIRC6, BPI, CEACAM8, CYBB/NOX2, DBNL, KLK15, MPO, and NCF2) contain mutations that could affect neutrophil effectiveness in 12 different breast cancers. Many infec tions seen in cancer patients are related to weakened function of neutrophils/phagosome-containing cells. Cancer-causing infections related to the mutations listed above include EBV, HCV, HPV, and H. pylori. The CYBB/NOX2 (cytochrome B-245, beta polypeptide) gene mutated in BR-M-045 breast cancer encodes a product that acts in host defense in phagosomes by generating H 2 O 2 .
29 Multiple noncancer-associated infections are specifically linked to CYBB/NOX2 activity and might exacerbate effects of mutation and of cancer-causing infections.
Breast cancer mutations affecting connections to immune responses and neurological sensing alter risks for infections. In at least 18 of the 103 breast cancers, a gene mutation affects the code for an inflammatory cytokine such as an interleukin (IL). These cytokines are essential signals to activate a longterm adaptive immune response (Fig. 2) . Other connections to innate and adaptive immunity are also damaged including Human Leukocyte Antigens (HLA) or the class II major histocompatibility complex transactivator (CIITA), an important regulator of histocompatibility genes (a total of six breast cancers in Table 3 ). Damage to these gene products can impair response to a long list of infections. Table 3 also contains many instances of specific individual signals essential for immunity that have sustained serious mutations in their genes. Even a neuroimmune response is damaged when genes encoding taste receptors (TAS1R and TAS2R genes) that sense bacterial endotoxins 30 are mutated in seven breast cancers (Table 3 ). Damage to cell adhesion and architecture genes associates with infections. In epithelial cells, CDH1 (cadherin 1, type 1) dynamically complexes with catenins, which regulates signalling pathways such as Phosphoinositide 3 kinase (PIK3)/Akt and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-KB). CDH1 also regulates multiple connections to the innate and adaptive immune systems 31 ( Fig. 2) . CDH1 gene mutations occur in three different breast cancers, and CDH1 protein is associated with a wide range of infections including some known to cause cancer (Table 3) . Maintaining epithelial barriers is a prime immunologic function of CDH1 because it participates in walling off infections and harmful agents to protect underlying structures. Adherens junctions formed by cadherins are known to inhibit lentivirus entry into cells. 32 In all the breast cancers, there were 16 mutations in 13 different cadherins. Many more mutations affected proteins that interact with cadherins.
Cell architecture and structure must be changed in order to accommodate viral infections. Every one of the 103 breast cancers have mutations affecting actin, the cytoskeleton, or its regulation. In order to establish a persistent infection, viruses must escape an immune response and pass through collagenrich extracellular structures, unfavorable environments, and structural barriers to reach targets. 3, 4 Many viruses have evolved the ability to manipulate the actin/membrane network in host cells to facilitate viral replication and then spread to new cells. Over 1/3 (35/103) breast cancers have damage to genes encoding one or more of three families of structural molecules (laminins, collagens, and fibronectin). Collagen alone is dependent on dozens of genes that have mutations in the breast cancers. Defects in these structural proteins could increase susceptibility to a broad range of microbial infections. In addition to viruses, infections that degrade these proteins include gram-positive bacteria, gram-negative bacteria, fungi, anaerobic bacteria, and parasites (Table 4) . Vaccinia virus (VACV), Rickettsia, and facultative intracellular bacteria Listeria monocytogenes and Shigella flexneri pervert host intracellular actin to promote transmission to new cells. 33 This suggests that the breast cancer genomes with deregulated cytoskeletal proteins or with considerable damage to the genes encoding cytoskeletal and extracellular signaling connections present many attractive targets for infection either before or after the cancer develops. In this instance, mutation and infection often work in the same direction in breast cancer cells.
Some ion channels have evolved to maintain homeostasis during infections. Because breast and other cancer cells have highly abnormal morphology and size, ion channel mutations may be essential for cancer cells to survive. In many breast cancers, ion channels with known associations to cell volume or morphology are mutated including NEDD4L (Table 3) The gene for intermediate filament-associated protein filaggrin (FLG) was mutated in eight breast cancers (Table 3) . FLG aggregates intermediate filaments and helps determine (Table 3) . Titin (TTN) is a giant protein with frequent mutations in breast and viral cancers that is important in cytoplasmic and nuclear structure (Table 3) . Thirty-four pentamers from a major capsid protein of HPV16 are shared with titin. 35 Alterations in chromatin structure associated with infections. In the 103 breast cancer exomes, at least 18 mutations in 18 different breast cancers directly affect the structure of one or more histones. Chromatin structure appears to be important in determining the local concentration of mutations, so histone gene mutations may be especially dangerous by improving access to host DNA and facilitating integration of viral genes.
The histone demethylase KDM4A is thought to be essential to maintain HHV-8 in the latent state. HHV-8 inhibits KDM4A, facilitating reactivation. Three breast cancers (Table 3 ) also inhibit KDM4A by mutation favoring HHV-8 reactivation. 36 MLL genes are histone methyl transferases that are common sites of viral integration. Fourteen breast cancers have mutations in MLL genes, and associations among their mutations exist with five viral infections including four tumor viruses (Table 3) .
SMARCA2 and SMARCA4 genes encode components of the SWI/SWF chromatin-remodelling complex needed to activate transcription of some genes. SMARCA2 or SMARCA4 (mutated in four breast cancers) are associated with two cancer retroviruses (HIV-1, HTLV-1) and HPV infection (Table 3) . Histone deacetylase mutations in breast cancers can alter chromatin structure and control of numerous infections by reversing acetylation reactions and are crucial for T-cell functions.
Breast cancer mutations affecting transcription and splicing are associated with infection. RNA polymerase III is a sensor for viral infection and is mutated in BR-M-045. Other examples of mutations affecting transcription are listed in Table 3 . RNA helicases (DDX genes) are essential for transcription, translation, RNA splicing, RNA transport, and RNA editing. DDX11, DDX20, and DDX47 are associated with HPV and/or EBV infections and are mutated in eight breast cancers. SRRM2 participates in splice site selection and is mutated in four breast cancers (Table 3) . SRRM2, a transactivator for HTLV-1 and HIV-1, modulates the alternative splicing complex so that it favors viral replication. 37 Breast cancer mutations in protein translation pathways are related to infections. Figure 3 is adapted from multiple sources. [13] [14] [15] Figure 3 illustrates that breast cancer mutations and infection have clear relationships based on the protein translation pathway steps affected. The steps targeted by mutation versus the steps targeted by infection are either identical or closely related. Hundreds of mutations affect the same pathways as viral and bacterial infections, and the figure shows potential complexities in a network of possible cooperation or antagonism between infections and DNA mutations. Virulence factors in the bacteria, MTb, Shigella, and salmonella ( Fig. 3) possess t-RNA nucleases that have the ability to reprogram translation initiation and global translation regulation. 38 Figure 3 further shows a few of the many connections between these translation pathways and the host immune response (yellow boxes). A PI3K signaling pathway that controls a rate-limiting step in protein translation and the figure shows these steps in green boxes. Links connect this pathway to innate immunity via the TLR3 receptor for innate immunity and the CDH1 receptor (Fig. 2) . Thirty-three breast cancers have a mutation that could affect PI3K and six breast cancers have mutations that could affect Akt activity in this pathway. PI3K is stimulated by tumor and other viruses (Table 3) . 39 PIK3 enzymes are also stimulated with ligands that activate TLR signaling so PI3K activation can be part of an innate immune defensive response to infection (Figs. 2  and 3 ). Infections and other mutations shown in Figure 3 can also affect steps prior to PI3K stimulation. mTORC1 serves as a central regulator of cell growth and division, coordinating signals from diverse processes including immunity, growth factors, nutrients, energy availability, redox status, lipid, nucleotide, and protein biosynthesis. mTORC1 signaling is sensitive to the presence of amino acids, insulin, and translocation to the lysosome. 14, 15 In the immune system, mTORC1 exerts extensive control over effector and memory differentiation of peripheral CD4 and CD8 T-cell effector functions. Invariant natural killer T cells, which bridge innate and adaptive immunity, are also controlled by mTORC1 signals and RPTOR as indicated in Figures 2 and 3 . 40, 41 Control of mTORC1 must be acute and active as determined by the Tuberous sclerosis (TSC1-TSC2) complex, 14, 15 but the control becomes deregulated in two breast cancers (Fig. 3) and in some viral infections such as HTLV-1. 42 EGFR (a receptor tyrosine kinase) is often dysregulated or mutated in breast cancer and a mutation in EGFR itself occurs in four breast cancers (Fig. 3) . EGFR itself is a co-receptor for HCMV and AAV6, 43 so EGFR mutations may affect susceptibility to these infections. However, the EGFR network exerts control over cell proliferation, protein translation, cell architecture, and survival, and so hundreds of mutations in the 103 breast cancers would have further impact on the ability of viruses to take over tightly regulated EGFR processes. Many viruses seize control over EGFR endocytosis or signaling to enter host cells, replicate, and evade immune responses ( Table 3) .
The removal of proteins after translation may be as tightly controlled as their production. F-box proteins are subunits of ubiquitin ligases that identify protein substrates for breakdown by the 26s proteasome. Twelve mutations in F-box proteins occur in the breast cancers giving viruses a head start in subverting protein removal. Several additional mutations more directly affect the proteasome (Fig. 2) .
Breast cancer mutations affecting the cell cycle can be associated with infection. Table 3 
includes examples of mutations affecting
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44 WEE1 mutation in three breast cancers prevents cell cycle arrest, disabling this defense mechanism against infection. Cell cycle arrest in infected cells is a major host defense against infections. 45 Other examples include the LATS2 (large tumor suppressor kinase 2) gene and protein phosphatase 2A (Table 3) .
Gene mutations affecting metabolism can be associated with infection. Many breast cancer mutations encode proteins that affect metabolism such as glycolytic enzymes, lipid biosynthesis, tissue-repair mediators, and NF-KB. There are often clear signaling connections to the immune system. Aerobic glycolysis controlled by an AKT-mTORC-HIF-1a pathway is the metabolic basis that enables myeloid cells to protect against secondary infections.
46
The breast cancer BR-M-079 has a mutation that causes the NR1D1 gene to begin transcription out of frame. NR1D1 (nuclear receptor subfamily 1, group D, member 1) encodes for a core member of the circadian clock emerging as a regulator of the immune response and metabolic pathways. The NR1D1 gene product is involved in the response to several microbes (Table 3) . 47 Even the prion disease Creutzfeld-Jakob disease 48 is increased by mutation in phospholipase PLCXD3 (lipid catabolism and signal transduction), which is mutated in BR-V-011.
Discussion
Different breast cancers contain mutations that alter responses to microbial infections, and microbial infections can alter responses to mutations and suppress the immune system. Even infections that are not directly linked to cancer may exacerbate damage from mutations and from other infections that do cause cancer. It is likely that there are many more mutations associated with infection because many mutations that affect the immune system have not been studied in the context of risks for infection (Fig. 1) . The goal of the present work is the ability to scan mutations in genomes for altered responses to a wide variety of infections. This can be done in few seconds. An emerging list of infection-mutation associations is readily scalable to routine human cancer genome analysis and may be helpful to determine infection susceptibility in other human genome analyses as well.
Mutation of the genes for host regulatory proteins can damage their control by the host, yet help infections bypass host regulatory circuits. This represents an alternative to the view that mutations cause cancer independently from infections. Instead, mutations caused by environmental or genetic damage increase the risks from both bacterial and viral infections and vice versa. One infection can increase damage from another or help control it. Genes encoding the signals needed to perform immune functions and to maintain cell barriers against infection represent most of the gene mutations found in this work and in hundreds of breast and other cancers. 3, 4, 49 Mutations in other host genes such as those encoding translation are not normally considered as part of innate immunity, but there are multiple and very clear connections. Mutations in host genes controlling rate-limiting steps in translation have clear connections to immune defenses and innate immunity but are not normally considered as antiviral defenses.
Based on Figures 2 and 3 , it is difficult to imagine that infections do not participate in the cancer process along with mutations. Infections interfere with corrections of errors; removal of damaged cells; immunity to known cancer viruses; control of the cell cycle, cell size, and shape; cell adhesion; cell metabolism, etc. Signaling pathways that are known to be involved in producing cancer are inhibited or damaged by infections as well as by mutations. In treating cancers, effects from infections should probably be considered along with effects from mutations. The population of cancer patients 50 included in this study contained nine patients with precancerous lesions such as DCIS. Patients with DCIS were not specifically identified in the original DNA sequencing report, 50 but all 103 patients, even those with only a few mutations, had associations with infections. These associations persisted despite the large range in age of the population of female sporadic cancer patients . There were differences as well in common tumor markers such as estrogen receptors, progesterone receptors, and HER2 status. 50 Moreover, there are probably many more mutation-infection associations because Figure 1 shows that thousands of mutations with likely associations could not be evaluated.
Infections such as HPV and EBV are known cancer viruses that are almost universal in the human population. Patient populations from the developing world who contributed the DNA sequences are at high risk from hepatitis viruses. Mutations that interfere with the control of these known cancer-causing infections would be reasonably expected to increase the number of cancers caused by these infections. High-risk gene mutations in BRCA1 and BRCA2 may have clear links to infection. In prophylactic tissue removed from high-risk BRCA1/2 patients, signs of infection are present even when there are no signs of cancer (B. Friedenson, unpublished observation). Histology photos of breast cancer cells suggest that they are often infected. Many breast cancers contain what look like hollow cells with gutted cytoplasm, a zone of clearing around the nucleus, changes in the cell cytoskeleton, and damage to primary cilia. Breast cancer cells also often contain other signs of viral infection: nuclear and cytoplasmic inclusion bodies, altered shapes, strangling of cytoplasm causing tentacles and projections, and chromatin redistribution or margination (B. Friedenson, unpublished observation).
Defenses against microbial infection are multilayered and depend on exposure and the condition of the immune system. Cancer gene mutations gather on common functions needed to control pathogens, so mutations create gaps in defenses. Responses to pathogens requiring multiple diverse host genes and proteins suggest how mutations could contribute to cancer
Journal of Genomes and exomes 2015:4 in infected individuals and how specific groups of infections might contribute to cancer in populations with particular gene mutations. In most cases, the gene with a mutation was essential to prevent the infection or was required in order for the infection to proceed. This argues that many infections cannot be due to random associations between mutated genes and microorganisms. Despite the above arguments, some infections probably occur after the cancer has developed and could represent cancer symptoms.
A practical application of this new genomic and structural evidence is that it may be feasible to eradicate occult infections and perhaps compensate for some gaps in immune defenses. Vaccinations against likely potential infections may be possible and helpful. Breast cancer cells with their damaged genes are easier to infect with some microbes than cells that do not have damage to the same genes. Therapy with oncolytic microbes that can take advantage of the deficits in breast cancer cells may destroy them with minimal damage to normal cells.
Many viral proteins target host proteins that have major impacts on the cell cycle of host infection targets. Viral proteins also target major regulatory proteins such as p53, RB, and the anaphase-promoting complex via diverse mechanisms. 51 Short stretches of viral protein amino acids (short linear motifs of 3-10 amino acids) 52 interact with such major host regulatory proteins. Short viral interacting sequences are abundant in the human proteome. They make viral interactions with critical host proteins much less specific and much less sensitive to host gene mutation than the complex processes that normally regulate host cells. Tables 1-4 suggest that altered responses to multiple infections seem to be the rule. The presence of weakened defenses in the face of large numbers of possible infections may factor into explanations for why cancer cells become resistant to targeted therapies. Removal of cancer cells related to one set of infections/mutations may clear the way for cancers associated with alternate different infections/mutations. Targeted therapy then clears the way for competing infections in the group of abnormal vulnerable cells so targeted therapy may fail. The diversity of exome mutations and infections that can potentially participate in carcinogenesis shows that cancer therapy should not consider cancer as a single-gene disease.
At least four well-studied cancer viruses (EBV, HBV, HCV, and HPV) are all represented equally in Table 1 . HIV-1 occurs about 50% more often and H. pylori about half as often. HPV cancer is thought to be stimulated by coexisting infections such as chlamydia and HSV-2. Figures 2 and 3 show abundant opportunities for more than one infection to become involved in cancer. Breast cancers share the same fraction of their gene mutations with HPV viral cancers of the cervix and with small-cell lung cancer, 4 a "non-viral" cancer attributed to smoking in almost all cases. 53 The results shows that multiple infections can be associated with breast cancers depending on the mutations present. DNA sequencing and microorganism associations were not randomly selected from the general population of breast cancer patients. Thus, the idea that these particular microorganisms are associated in general with breast cancer in roughly these proportions would depend on the mutations and exposures to infection within the population. This requires further study.
The disease stage and type of cancer were not controlled in the 103 breast cancers so infection-mutation associations cannot yet be assigned to any specific stage of the disease. The present study was also quite small but should be easy to expand to larger groups. Another limitation is that the results are biased by the amount of study that each mutation-infection association has received so that genes or infections having the greatest interest are more likely to be represented. The number of infections that can potentially infect humans is probably close to limitless, but there are only a finite number of critical infections in the groups of breast cancer patients from Mexico and Vietnam.
Damage to host cell-protective signals account for high percentages of mutations found in breast cancer cells but must be rationalized with the widely held belief that 10 mutations are sufficient to cause cancer and that additional mutations occur as time passes. 54 However, the vast differences in the numbers of mutations in a series of breast cancers show no relationship to the age of the patient, 55, 56 suggesting vastly different mutation rates. Evidence supporting 10 mutations comes largely from experiments using relatively homogeneous cell cultures that contrast with heterogeneous cancers. Highly important and significant advances have resulted from cancer cell culture experiments, and cancer cell cultures are an invaluable resource. However, relying only on events within a single cell might limit the conclusions. In cell culture, there are only fragments of an immune system; natural protection is largely gone against infection or against abnormal cells; many anatomical and cellular barriers to infection are removed and important protective interactions with the extracellular matrix are not possible. Nonetheless, antibiotics and sterile technique preclude infection. In many experiments, architectural barriers within the cell to cancer-causing infections are overcome by forcible DNA transfection. Normal host cells in a culture without systems that protect from cancercausing infections may require far fewer mutations to develop cancer. Moreover, cancers strategically placed in the immune system may require fewer mutations than other cancers because the malignancy itself impairs immunity. The success of the drug Gleevec for CML with reciprocal translocated chromosome fragments, has not been widely duplicated in other cancers, suggesting that most cancers are different from CML.
Conclusions
Many mutations in breast cancer alter susceptibility to infection. Change in infection susceptibility is a common thread connecting cancer mutations in diverse functions. Infections and mutations can both contribute to cancer because they deregulate the same pathways. Interventions may be possible to prevent infections from cooperating with mutations to cause further cancer, metastasis, or other complications.
